The heavy selling pressure might have exhausted for Replimune Group, Inc. (REPL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street...
Replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings...
Replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through...
The consensus price target hints at an 87.9% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
Replimune Group, Inc. (REPL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
This billionaire-guided hedge fund went bargain-shopping in the second quarter.
Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous...
WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
WOBURN, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab),...